Zhu and his team indicated that knockdown FGL2 in mice slugged the progression of lung cancer, inhibited CXCL12-mediated cumulation of MDSCs in TME, and weakened the role of CAFs 80. This evidence concerns the gene FGL2 and lung carcinoma.